Navigation Links
Cardiometabolic Health Congress Expert Faculty Weigh in on FDA Advisory Panel Recommendation for Novel Weight-Loss Medication
Date:2/28/2012

BOSTON, Feb. 28, 2012 /PRNewswire/ -- The Food and Drug Administration advisory panel voted on Wednesday, Feb. 22, 2012, in favor of recommending that the FDA approve the prescription obesity drug Qnexa.  If approved, this will be the first time in more than a decade that a prescription weight-loss medication receives FDA approval.  This landmark recommendation prompted the 2012 Cardiometabolic Health Congress (CMHC) expert faculty to weigh in on the implications of the potential approval of this novel obesity medication.

"I am pleased that the FDA advisory panel has been able to see a way forward to support therapies that will help patients and clinicians confront the obesity epidemic. While pharmacotherapy is not appropriate for everyone, it is important to have options to help patients," said Richard Pratley, MD, professor of medicine and director of the Diabetes and Metabolism Translational Medicine Unit at the University of Vermont College of Medicine in Burlington, VT.

Robert H. Eckel, MD, co-chair of the 2012 CMHC and professor of medicine at the University of Colorado Anschutz Medical Campus, said, "I think the decision was a good one and is important for the academic and medical educational missions related to obesity and cardiovascular disease." 

"It is a very interesting development and a bit surprising," said Deepak L. Bhatt, MD, Chief of Cardiology, VA Boston Healthcare System, associate professor of medicine at Harvard Medical School, and senior investigator, TIMI Study Group.  He added, "I still think that a large study evaluating cardiovascular safety is needed."

The Chief Scientific Officer for the Association of Black Cardiologists and professor of clinical medicine at Tulane University School of Medicine, Keith C. Ferdinand, MD, cautioned that, "The fight against obesity needs to be multifactorial, including new medications. As a cardiologist, however, I consider it paramount that all clinicians remember to monitor our patients closely for cardiac risks, including heart rate and blood pressure, and not just treat obesity as a cosmetic concern."

Harold Bays, MD, medical director and president, Louisville Metabolic and Atherosclerosis Research Center, Inc., stated, "This [FDA advisory panel] decision validates the emerging recognition that adiposity, or fat weight gain, creates adipose tissue dysfunction or 'sick fat' which directly and indirectly contributes to metabolic disease.  As importantly, the Qnexa development program objectively supports how fat weight reduction improves adipose tissue function, effectively treats the metabolic and immune abnormalities of 'sick fat,' and thus improves the most common metabolic diseases encountered in clinical practice, such as elevated glucose, blood pressure, and dyslipidemia - all major cardiovascular disease risk factors."

The Centers for Disease Control and Prevention state that over 35 percent of American adults are obese, with 5 percent being considered morbidly obese. In addition, 33 percent of American adults are overweight.  In response to this obesity epidemic, the CMHC, the most influential U.S.-based medical and scientific conference in its field, gathers over 50 world-renowned experts in cardiometabolic health each year to educate clinicians on current strategies for the prevention, diagnosis and management of obesity, type 2 diabetes, atherosclerosis, hypertension, dyslipidemia, thrombosis, acute coronary syndrome, chronic kidney disease and related comorbidities.

"It is striking that the CMHC has become the undisputed leader in conferences that address the most important metabolic derangements of our time, due largely to the strength of the faculty and their interactions with an engaged audience," said James Gavin III, MD, PhD, CEO and Chief Medical Officer of Healing Our Village, Inc., and clinical professor of medicine, Emory University School of Medicine.

The 7th Annual CMHC will convene Oct. 10-13, 2012 in Boston, MA; it is co-chaired by George L. Bakris, MD; Christie M. Ballantyne, MD; Robert H. Eckel, MD; and Jay S. Skyler, MD, MACP.

For more information, contact Dina Kouveliotes at dk@cardiometabolichealth.org or 877.571.4700 or visit www.cardiometabolichealth.org


'/>"/>
SOURCE Cardiometabolic Health Congress
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
4. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Tone Deafness Explained, from the Harvard Health Letter
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
9. ViroPharma to Present at Three Upcoming Healthcare Conferences
10. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for ... Company also filed its Quarterly Report on Form 10-Q for ... and Exchange Commission today. --> ... --> --> Net sales for the three ... to $5.4 million from $2.8 million for the three months ...
(Date:2/11/2016)... FRANCISCO , Feb. 11, 2016   Health ... advancement of new health technologies, announced today " 10 ... achievements in health tech over the past ten years.   ... For nearly a decade, Health 2.0 has served as ... showcased and connected with thousands of technologies, companies, innovators, ...
(Date:2/11/2016)... WESTPORT, Conn. , Feb. 11, 2016  AfterPill.com ... decision to recommend alcohol abstinence for all women who ... women in the U.S. each year and raises the ... --> --> According to the ... U.S., 70% of women of child-bearing age, who have ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 12, 2016 , ... Fitbody Personal Training offers ... fun and exciting way to get fit and healthy. Located in Phoenixville, PA, the ... for a class designed for horseback riders who want to lose weight and tone ...
(Date:2/11/2016)... ... February 11, 2016 , ... SPH Analytics announced ... analytics leader’s population health solutions, MDinsight® and IndiGO®, for its primary care clinicians. ... system. Details of the contract were not disclosed. , As the healthcare market ...
(Date:2/11/2016)... ... February 11, 2016 , ... Dr. Sadati’s recent ... cosmetic procedures. Along with performing procedures, the magazine also highlights that Dr. Sadati ... procedures. One of the most common procedures he performs is his natural facelift. ...
(Date:2/11/2016)... TN (PRWEB) , ... February 11, 2016 , ... ... cleaning business to a new market, and it’s the buildings of Nashville that will ... that when I needed to relocate to Nashville, there was no question that I ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... diabetes has been gearing up for their simultaneous grand openings in March. All ... right now that you’re probably wondering, is reversing diabetes possible? According to this ...
Breaking Medicine News(10 mins):